The University of Chicago Header Logo

Connection

Hans Schreiber to Neoplasms

Back to Details
This is a "connection" page, showing publications Hans Schreiber has written about Neoplasms.
Hans Schreiber
Connection Strength
2.856
Neoplasms
  1. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
    View in: PubMed
    Score: 0.269
  2. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
    View in: PubMed
    Score: 0.194
  3. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
    View in: PubMed
    Score: 0.180
  4. Editorial overview: tumour immunology. Curr Opin Immunol. 2015 Apr; 33:ix-xi.
    View in: PubMed
    Score: 0.171
  5. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015 Apr; 33:112-9.
    View in: PubMed
    Score: 0.170
  6. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
    View in: PubMed
    Score: 0.150
  7. Targeting stroma to treat cancers. Semin Cancer Biol. 2012 Feb; 22(1):41-9.
    View in: PubMed
    Score: 0.137
  8. Tumor-specific immune responses. Semin Immunol. 2008 Oct; 20(5):265-6.
    View in: PubMed
    Score: 0.110
  9. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008 Nov; 118(11):3574-81.
    View in: PubMed
    Score: 0.110
  10. Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
    View in: PubMed
    Score: 0.108
  11. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
    View in: PubMed
    Score: 0.106
  12. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008 Mar 01; 68(5):1563-71.
    View in: PubMed
    Score: 0.105
  13. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006 Apr; 18(2):226-31.
    View in: PubMed
    Score: 0.091
  14. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec; 14(6):433-9.
    View in: PubMed
    Score: 0.084
  15. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004 May 13; 23(22):3972-9.
    View in: PubMed
    Score: 0.081
  16. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
    View in: PubMed
    Score: 0.080
  17. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol. 2003 Dec; 15(6):725-30.
    View in: PubMed
    Score: 0.078
  18. Immunodominance and tumor escape. Semin Cancer Biol. 2002 Feb; 12(1):25-31.
    View in: PubMed
    Score: 0.069
  19. Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s.
    View in: PubMed
    Score: 0.065
  20. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 2000 Oct; 10(5):351-7.
    View in: PubMed
    Score: 0.063
  21. Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
    View in: PubMed
    Score: 0.059
  22. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
    View in: PubMed
    Score: 0.059
  23. A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. 2019 04 01; 29(4):307-319.
    View in: PubMed
    Score: 0.057
  24. Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature. 2017 05 04; 545(7652):98-102.
    View in: PubMed
    Score: 0.049
  25. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
    View in: PubMed
    Score: 0.039
  26. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
    View in: PubMed
    Score: 0.038
  27. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther. 2012 Mar; 20(3):652-60.
    View in: PubMed
    Score: 0.034
  28. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am. 2006 Jun; 20(3):567-84.
    View in: PubMed
    Score: 0.023
  29. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005 Mar 07; 201(5):779-91.
    View in: PubMed
    Score: 0.021
  30. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol. 2003 Jan; 33(1):19-28.
    View in: PubMed
    Score: 0.018
  31. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech. 2001 Feb 15; 52(4):387-95.
    View in: PubMed
    Score: 0.016
  32. Active immunization against cancer cells: impediments and advances. Semin Oncol. 1998 Dec; 25(6):697-706.
    View in: PubMed
    Score: 0.014
  33. Tumor antigens. Annu Rev Immunol. 1992; 10:617-44.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.